Blair William & Co. IL Sells 22,172 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Blair William & Co. IL trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,950 shares of the medical research company’s stock after selling 22,172 shares during the period. Blair William & Co. IL’s holdings in NeoGenomics were worth $1,449,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in NEO. Vanguard Group Inc. lifted its stake in NeoGenomics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock worth $234,673,000 after acquiring an additional 195,793 shares during the period. State Street Corp lifted its holdings in NeoGenomics by 1.6% during the third quarter. State Street Corp now owns 4,958,582 shares of the medical research company’s stock worth $73,139,000 after buying an additional 80,449 shares during the period. Geode Capital Management LLC boosted its position in NeoGenomics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock valued at $45,022,000 after acquiring an additional 36,136 shares in the last quarter. Segall Bryant & Hamill LLC boosted its position in NeoGenomics by 11.6% during the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company’s stock valued at $34,836,000 after acquiring an additional 220,415 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of NeoGenomics by 2.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company’s stock valued at $28,225,000 after acquiring an additional 39,740 shares during the period. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Stock Up 0.7 %

NEO stock opened at $9.42 on Thursday. The firm’s fifty day moving average is $11.63 and its 200 day moving average is $14.21. The firm has a market cap of $1.21 billion, a PE ratio of -15.19 and a beta of 1.28. NeoGenomics, Inc. has a one year low of $8.98 and a one year high of $19.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. On average, research analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of recent research reports. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective on the stock. Piper Sandler decreased their target price on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Needham & Company LLC cut their price target on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. Finally, The Goldman Sachs Group decreased their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.